Biosimilars | Overview & Forecast | G7 | 2016

launch Related Market Assessment Reports

• Biosimilars – Current Treatment – Immunology

  November 2023

  Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…

• Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape

  September 2023

  The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 696 currently available and novel biosimilar products, detailing…

• Biosimilars – Forecast – Nephrology

  September 2023

  In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (…

• Biosimilars – Forecast – Endocrinology

  In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…

• Biosimilars – Forecast – Respiratory

  In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…